Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 8/20 | 0.53 |
| ▸ | BDKRB1 | P46663 | 11/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | CDK16 | Q00536 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14084940 | 0.93 | BDKRB1 (0.49) | GSK3BBDKRB1 | |
| SCHEMBL6046168 | 0.92 | BDKRB1 (0.57) | BDKRB1 | |
| SCHEMBL4701564 | 0.89 | GSK3B (0.47) | GSK3BBDKRB1 | |
| SCHEMBL6045909 | 0.89 | BDKRB1 (0.50) | BDKRB1 | |
| SCHEMBL14084950 | 0.87 | BDKRB1 (0.62) | BDKRB1 | |
| SCHEMBL6045832 | 0.86 | BDKRB1 (0.49) | GSK3BBDKRB1 | |
| SCHEMBL14084926 | 0.86 | BDKRB1 (0.59) | GSK3BBDKRB1DYRK1A | |
| SCHEMBL6046001 | 0.85 | BDKRB1 (0.60) | BDKRB1 | |
| SCHEMBL4789665 | 0.83 | BDKRB1 (0.53) | BDKRB1 | |
| SCHEMBL6046052 | 0.82 | BDKRB1 (0.49) | BDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060281733-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carvoxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | ELAN PHARMACEUTICALS, INC. | 2006-12-14 | — | — | US | claimed |
| US-20060281733-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carvoxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | ELAN PHARMACEUTICALS, INC. | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281733-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carvoxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | BDKRB1, BDKRB2, CNR1 | GSK3B 4511/4885BDKRB1 1/4885CDK2 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.